Israel

BMI View: While Teva's Q112 results were not terrible compared to Q411, as revenues and profits both saw reasonable growth, and considering the recent acquisitions of Cephalon and Taiyo,... 2012-05-10

BMI View: Israel will continue to attract investment because of a strong culture of entrepreneurism that has led to a large number of life science start-up companies. In particular,... 2012-04-27

BMI View: Following widespread protests in mid-2011, the Israeli government has been under significant pressure to spend more on housing, healthcare and education. While it was not... 2012-02-17

BMI View: Teva Pharmaceutical Industries continued its lacklustre performance in the last quarter of 2011. Its results showed that very little had improved from BMI's and the market's... 2012-02-16

BMI View: While Israel has historically been a cheap and effective site for clinical trials, it is becoming increasingly expensive compared to emerging markets and it also cannot compete... 2011-11-29

BMI View: Our view that industrial action in Israel would result in an increase in public healthcare expenditure has played out. The government is promising an additional ILS2.7bn (US$764mn)... 2011-11-10

BMI View: We remain positive about Teva Pharmaceutical's short- and medium-term future as the patent cliff approaches and austerity measures and rational prescription increases generic... 2011-11-03

BMI View: The street protests in Israel have greater political and economic implications for the country's future than healthcare provision specifically, despite it being one of the... 2011-08-16

BMI View: Teva's Q211 results are unimpressive but expected given the company's poor Q111 performance. However, BMI remains positive about the company's long-term future as austerity... 2011-07-28

BMI View: Israel claims to have a very efficient healthcare system that means it does not need to spend as much of its GDP on healthcare. In truth, the government's fiscal austerity... 2011-05-04